World Asthma Drug Market Analysis & Forecast Available in In-demand Report by GlobalData Published at MarketPublishers.com

Share Article

Topical market research report “PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023” elaborated by GlobalData has been recently published at MarketPublishers.com.

TD The Market Publishers Ltd

http://marketpublishers.com/

The average number of people dying from asthma each year amounts to around 250,000. However, this figure could be much lower if an effective treatment is introduced. Over the last ten years, the world asthma market showed sluggish growth due to the rising generic competition and market oversaturation with standard therapies, including inhaled corticosteroids (ICSs), short-acting beta-agonists (SABAs), leukotriene modifiers and inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs). However, the development of seven novel targeted biologic agents as well as ICS and ICS/LABA next-generation inhaler therapies are forecast to drive the world asthma market in the next decade.

Merck, AstraZeneca, Teva, GSK, Boehringer Ingelheim, Roche and Novartis are the leading players within the asthma market. The companies are focused on Xolair (omalizumab), a biologic therapy which already went beyond the USD 1 billion mark in sales volumes.

GSK has the most successful portfolio of asthma drugs, with Advair being the major one. Advair's patent is unlikely to expire in the near future, although the patent cliff for the drug formulations and the Diskus inhaler is expected in the reviewed period. Besides, Breo Ellipta (fluticasone furoate and vilanterol), developed by GSK, is about to take lead in the world asthma market.

Meantime, Merck is likely to lose its major position in the asthma market given the weak pipeline, which is concentrated on immunotherapies development, along with the rapid generic erosion of the company's blockbuster drug, Singulair.

Given the growth of environmental diseases around the globe, the number of people suffering from the asthma is expected to achieve 400 million patients in 2025.

Topical market research report “PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023” elaborated by GlobalData has been recently published at MarketPublishers.com.

Report Details:

Title: PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023
Published: August, 2014
Pages: 383
Price: US$ 10,995.00
http://marketpublishers.com/report/pharmaceuticals/drugs/pharmapoint-asthma-global-drug-forecast-n-market-analysis-to-2023.html

The topical report includes an extensive assessment of the world asthma market and presents an in-depth overview of the disease, providing details on main symptoms, diagnosis and treatment guidelines. The report highlights the competitive environment alongside profiling the main market players, reviews the key market drivers, constraints and challenges. Besides, the research is enriched with detailed pipeline analysis, including unique information on the recent developments and the most promising pipeline drugs. It unveils the innovative products and technologies and outlines the future opportunities in the marketplace. Forecast figures for global asthma drug sales through 2023 are offered in the report, too.

Reasons to buy:

  • Full knowledge of the world asthma market helps to develop effective business strategies.
  • Identify the leading market players and find potential partners.
  • Gain key insights into the market development till 2023.
  • Understanding the competitive scenario helps to increase sales activities and formulate effective marketing strategies.
  • Define investment opportunities by receiving an access to the detailed asthma market assessment, including analysis of the main market dynamics.
  • Receive up-to-date information on the recent product developments and innovative technologies.

More in-demand reports by the publisher can be found at GlobalData page.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Natalia Aster
Follow us on